Monrol Partner Telix Report First Patient Dosing of TLX250 (177Lu-DOTA-girentuximab) in P-II (STARLITE 2) Study for Clear Cell Renal Cell Carcinoma
Shots:
- The first patient has been dosed in the P-II (STARLITE 2) study to evaluate TLX250 + Opdivo in 29 patients with ccRCC. Monrol will supply Lu-177 n.c.a to Telix to manufacture clinical doses of TLX250 for the P-II (STARLITE 2) study at MSK Cancer Center in New York while TLX250-CDx will also be used to image CA9 expression for the P-II (ZIRCON) trial in its Istanbul facility
- The 1EPs of the P-II (STARLITE 2) study is to identify the safety & efficacy of combination therapy as assessed by the tumors compared to SoC alone
- Additionally, the objective of (the ZIRCON) trial is to evaluate the sensitivity and specificity of PET/CT imaging with TLX250-CDx to non-invasively detect ccRCC
Ref: Businesswire | Image: Monrol
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
